210 related articles for article (PubMed ID: 35475786)
1. PRAME Expression in Junctional Melanocytic Proliferations of the Conjunctiva: A Potential Biomarker for Primary Acquired Melanosis/Conjunctival Melanocytic Intraepithelial Lesions.
Huang YY; Hrycaj SM; Chan MP; Stagner AM; Patel RM; Bresler SC
Am J Dermatopathol; 2022 Oct; 44(10):734-740. PubMed ID: 35475786
[TBL] [Abstract][Full Text] [Related]
2. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
3. PRAME expression in melanocytic lesions of the conjunctiva.
Šekoranja D; Hawlina G; Pižem J
Histopathology; 2021 Dec; 79(6):989-996. PubMed ID: 34268800
[TBL] [Abstract][Full Text] [Related]
4. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
[TBL] [Abstract][Full Text] [Related]
5. Differential immunoreactivity of melanocytic lesions of the conjunctiva.
Sharara NA; Alexander RA; Luthert PJ; Hungerford JL; Cree IA
Histopathology; 2001 Oct; 39(4):426-31. PubMed ID: 11683945
[TBL] [Abstract][Full Text] [Related]
6. Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: Clinicopathologic analysis of 29 cases.
Sugiura M; Colby KA; Mihm MC; Zembowicz A
Am J Surg Pathol; 2007 Feb; 31(2):185-92. PubMed ID: 17255762
[TBL] [Abstract][Full Text] [Related]
7. Unusual conjunctival melanocytic proliferations. Report of five cases and review of the literature.
Eder A; Milman T; Mudhar HS; Lally SE; Shields CL; Bui K; Wells JR; Grossniklaus HE
Surv Ophthalmol; 2024; 69(2):230-240. PubMed ID: 37890676
[TBL] [Abstract][Full Text] [Related]
8. Therapy of melanocytic conjunctival tumors.
Halas JM; Svetlosakova Z; Babal P
Bratisl Lek Listy; 2013; 114(8):446-50. PubMed ID: 23944618
[TBL] [Abstract][Full Text] [Related]
9. Histological criteria for grading of atypia in melanocytic conjunctival lesions.
Maly A; Epstein D; Meir K; Pe'er J
Pathology; 2008 Dec; 40(7):676-81. PubMed ID: 18985522
[TBL] [Abstract][Full Text] [Related]
10. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture.
Shields JA; Shields CL; Mashayekhi A; Marr BP; Benavides R; Thangappan A; Phan L; Eagle RC
Ophthalmology; 2008 Mar; 115(3):511-519.e2. PubMed ID: 17884168
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
12. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
13. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profiling including beta-catenin in conjunctival melanocytic lesions.
Reddy HS; Keene CD; Chang SH; Jian-Amadi A; Cimino PJ
Exp Mol Pathol; 2017 Apr; 102(2):198-202. PubMed ID: 28161440
[TBL] [Abstract][Full Text] [Related]
15. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
16. Incidence of melanocytic lesions of the conjunctiva in a review of 10 675 ophthalmic specimens.
Novais GA; Fernandes BF; Belfort RN; Castiglione E; Cheema DP; Burnier MN
Int J Surg Pathol; 2010 Feb; 18(1):60-3. PubMed ID: 18611943
[TBL] [Abstract][Full Text] [Related]
17. Conjunctival Melanocytic Lesions.
Bresler SC; Simon C; Shields CL; McHugh JB; Stagner AM; Patel RM
Arch Pathol Lab Med; 2022 May; 146(5):632-646. PubMed ID: 34424954
[TBL] [Abstract][Full Text] [Related]
18. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
19. PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience.
Carvajal P; Zoroquiain P
Pathol Res Pract; 2023 Oct; 250():154776. PubMed ID: 37696245
[TBL] [Abstract][Full Text] [Related]
20. Benign conjunctival melanocytic lesions. Clinicopathologic features.
Folberg R; Jakobiec FA; Bernardino VB; Iwamoto T
Ophthalmology; 1989 Apr; 96(4):436-61. PubMed ID: 2657539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
